GOLETA, Calif.–(BUSINESS WIRE)–$INGN #AirwayClearance—Inogen, Inc. (Nasdaq: INGN), a leading medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms.
“Naga’s deep background in digital health and connected device innovation makes him an ideal fit for Inogen as we continue to expand our technology leadership,” said Kevin Smith, President and Chief Executive Officer of Inogen, “His ability to integrate software, data, and devices to improve user experiences will be instrumental in advancing our pipeline and strengthening our competitive positioning in today’s underserved respiratory care market. We look forward to his contributions as a key member of our leadership team.”
Mr. Rameswamy brings more than two decades of leadership in the medical device industry spanning innovation, R&D, and digital transformation. Prior to Alcon, he spent nearly twenty years at GE Healthcare, culminating as Vice President of Digital Health Engineering. He has advanced secure device connectivity, remote diagnostics, fleet reliability, and care management platforms across diagnostic imaging, ultrasound, and patient monitoring modalities. He has scaled global engineering teams and partnered closely with quality, regulatory, manufacturing, sales, service, and cloud infrastructure to deliver compliant, secure, and intuitive products & solutions that improve serviceability, extend product lifecycles, and enhance experiences for patients, caregivers, and clinicians.
“I am honored to join Inogen and its exceptional team. The company’s mission in respiratory care, its global reach, and its platform of trusted products provide a strong foundation for continued impact,” said Mr. Rameswamy, “I look forward to advancing our digital health and technology initiatives, building on the impressive programs already in place to deliver better experiences for patients and partners as we reach more people suffering from respiratory conditions.”
About Inogen
Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.
For more information, please visit www.inogen.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that are not historical facts, including, but not limited to, statements regarding Inogen’s future business plans, market opportunities, financial outlook, growth strategies, and anticipated operational results, are forward-looking statements. Words such as “aims,” “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks and uncertainties relating to the potential benefits of Inogen’s collaboration with Yuwell; market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the period ended December 31, 2024, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.
Contacts
ir@inogen.net
